My research aims to understand the role of brain chemistry in mental illness and to identify different subtypes of Illness that might show different responses to drug treatments. In particular I am interested in how differences in brain glutamate levels may predict response to antipsychotic drugs and antidepressants. I am also involved in research on the gut microbiome and it's role in depression and anxiety, as well as on ketamine and psilocybin in the treatment of depression and post-traumatic stress disorder (PTSD). My research encompasses a variety of methods including clinical trials, magnetic resonance imaging (MRI) imaging and psychological testing.

Please see my Research Staff Profile for more detail

Key publications:

• Stone et al., 2007. Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. Journal of  Psychopharmacology.
• Stone et al., 2012. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Molecular Psychiatry.
• Egerton et al., 2012. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmology.